

Roquinimex

Catalog No: tcsc3169



Available Sizes

Size: 10mg

Size: 50mg



Specifications

CAS No:

84088-42-6

Formula:

$C_{18}H_{16}N_2O_3$

Pathway:

Apoptosis

Target:

TNF Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 83.3 mg/mL (270.17 mM)

Alternative Names:

Linomide;FCF89;ABR212616

Observed Molecular Weight:

308.33


Product Description

Roquinimex (Linomide; PNU212616; ABR212616) is a quinoline derivative immunostimulant which increases NK cell activity and macrophage cytotoxicity; inhibits angiogenesis and reduces the secretion of TNF alpha.

IC50 value:

Target: TNF alpha

Prophylactic administration of DSS-treated mice with roquinimex significantly reduced clinical signs of colitis, MDS and the CH-reduction. Moreover, in roquinimex treated animals, the MPO activity was significantly reduced by more than 50% compared to DSS control mice. Notably, therapeutic administration of roquinimex in DSS-treated mice also significantly inhibited the MDS, CH-reduction and MPO activity [2]. Linomide, a synthetic immunomodulator, at concentrations effective in vivo reduces the number of MBP-reactive TNF-alpha and increases MBP-reactive IL-10 and TGF-beta mRNA expressing MNC from MS patients' blood when analysed in vitro. Compared to dexamethasone, Linomide up-regulated levels of blood MNC expressing mRNA of TGF-beta after culture in presence of MBP [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!